SEPIA-ACS-TIMI 42 evaluated the efficacy and safety of otamixaban, a direct factor Xa inhibitor, in patients with non-ST-elevation acute coronary syndrome.
Otamixaban for the treatment of patients with non-ST-elevation acute coronary syndromes (SEPIA-ACS1 TIMI 42): a randomised, double-blind, active-controlled, phase 2 trial
Lancet. 2009 Sep 5;374(9692):787-95.
Prognostic Performance of a High-Sensitivity Cardiac Troponin I Assay in Patients with Non-ST-Elevation Acute Coronary Syndrome. Clin Chem. 2014 Jan;60(1):158-64.
Modes and timing of death in 66 252 patients with non-ST-segment elevation acute coronary syndromes enrolled in 14 TIMI trials. Eur Heart J. 2018 Nov 7;39(42):3810-3820.